By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Medivation, Inc. 

525 Market Street
36th Floor
San Francisco  California  94105  U.S.A.
Phone: 415-543-3470 Fax: 415-543-3411


Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzheimer's disease and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. Medivation recently announced that it plans to continue further development of Dimebon in patients with mild-to-moderate Huntington's disease based on the positive results seen in its Phase 2 trial.

For more information, please visit us at

Key Statistics

Ownership: Public

Web Site: Medivation, Inc.
Employees: 18
Symbol: MDVN



Company News
Wall Street Bullish On Medivation, Inc. (MDVN) After Xtandi Approval 9/12/2014 6:47:54 AM
Medivation, Inc. (MDVN) Banks $90 Million From Astellas Pharma Inc. (ALPMY) As FDA Expands Use Of Prostate Cancer Drug 9/11/2014 9:15:46 AM
Medivation, Inc. (MDVN) Announces Participation At Upcoming Investor Conference 8/26/2014 10:14:20 AM
Medivation, Inc. (MDVN) Reports Second Quarter Financial Results And Provides Corporate Update 8/8/2014 10:27:43 AM
Medivation, Inc. (MDVN) Announces Second Quarter 2014 Financial Results Teleconference On August 7, 2014 7/25/2014 9:27:00 AM
Medivation, Inc. (MDVN) Announces Change In Executive Management Team 7/11/2014 10:22:10 AM
Medivation, Inc. (MDVN) Again Voted Among Top Workplaces In The SF Bay Area 6/17/2014 12:26:22 PM
Medivation, Inc. (MDVN) Founder, President and Chief Executive Officer David Hung, M.D. Named An EY Entrepreneur Of The Year™ 2014 Award Winner In Northern California 6/12/2014 10:20:50 AM
Medivation, Inc. (MDVN) Release: The New England Journal of Medicine Publishes Results From Phase 3 PREVAIL Trial Of Enzalutamide In Men With Chemotherapy-Naive Metastatic Prostate Cancer Progressing Despite Androgen Deprivation Therapy 6/2/2014 10:46:45 AM
Medivation, Inc. (MDVN) Announces Participation At Upcoming Investor Conferences 5/13/2014 10:02:43 AM